WuXi buys NextCODE; Alnylam and Isis re-up their RNA alliance;

@FierceBiotech: Incyte, Agenus partner on immuno-oncology targets in $410M deal. More | Follow @FierceBiotech

@JohnCFierce: Hey, UK readers. I'm moderating a panel Feb 4 at the Queen Mary Innovation Centre on #biotech finance. Invite only. More | Follow @JohnCFierce

@DamianFierce: Biogen signs a $30M deal with Columbia U. to sequence the genomes of "unusual" patients. Release | Follow @DamianFierce

> Chinese CRO WuXi PharmaTech ($WX) bought NextCODE Health for $65 million in cash, bolstering its genomics heft by integrating the deCODE spinout. News

> Alnylam Pharmaceuticals ($ALNY) and Isis Pharmaceuticals ($ISIS) have extended the RNA-focused partnership, cross-licensing their intellectual property to develop new targeted therapeutics. More

> Regeneron ($REGN) and Sanofi ($SNY) say alirocumab, their in-development cardio drug, performed well as a once-a-month therapy for high cholesterol. Item

Medical Device News

@FierceMedDev:  PureTech bumps its early life science funds up to $107M. Story | Follow @FierceMedDev

@EmilyWFierce: Adaptive Biotechnologies snatches up Sequenta to gain ground in cancer immunosequencing Story | Follow @EmilyWFierce

> In a win for Spectranetics, Covidien's to-be-divested drug-coated balloon earns CE mark. News

> C.R. Bard pushes for delay of vaginal mesh trial after judge's call for settlement. Article

Pharma News

@FiercePharma: Catterton offloads PetVet hospital network to Canadian pension plan for $440M. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Court to give speedy answer in Actavis bid to yank old Namenda off market. Report | Follow @CarlyHFierce

> Generics could sink AbbVie below analysts' 2015 estimates. Report

> FDA draws line in sand over its orphan drug policies. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.